+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Therapeutics Market - Global Forecast 2026-2032- Product Image
Multiple Myeloma Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Multiple Myeloma Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674082
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Myeloma Therapeutics Market is projected to reach USD 26.38 Billion in 2026. It is expected to continue growing at a CAGR of 7.36%, reaching USD 40.48 Billion by 2032.

Multiple myeloma therapeutics are advancing rapidly as the treatment paradigm moves from proteasome inhibitors, immunomodulatory drugs, corticosteroids, and anti-CD38 antibodies toward highly targeted immunotherapies and increasingly personalized sequencing strategies.

The disease remains a material oncology burden. GLOBOCAN 2022 reported roughly 188,000 new multiple myeloma cases and more than 120,000 deaths worldwide, while the American Cancer Society estimated about 35,780 new U.S. cases in 2024. Longer survival, earlier diagnosis, improved risk stratification, and broader use of continuous therapy are expanding treated prevalence and increasing demand for durable, tolerable, and accessible regimens.

Market momentum is being shaped by quadruplet induction regimens, maintenance therapy, bispecific antibodies, CAR-T cell therapies, antibody-drug conjugate research, and next-generation agents for relapsed or refractory multiple myeloma. For stakeholders, the core opportunity lies in improving depth of response, extending progression-free survival, reducing treatment burden, supporting measurable residual disease assessment, and widening access across mature and emerging health systems.

Transformative Shifts in the Multiple Myeloma Landscape

The multiple myeloma treatment landscape is undergoing a structural shift from sequential chemotherapy-based management to immune-directed, response-adapted therapy. Anti-CD38 antibody combinations have moved deeper into frontline care, while BCMA-targeted CAR-T therapies and bispecific antibodies have changed expectations for heavily pretreated patients.

Regulatory momentum is notable. The U.S. FDA has approved BCMA-directed CAR-T therapies such as idecabtagene vicleucel and ciltacabtagene autoleucel, along with bispecific antibodies including teclistamab and elranatamab targeting BCMA and talquetamab targeting GPRC5D. These approvals validate multi-target immunotherapy strategies and intensify competition around efficacy, safety management, manufacturing reliability, patient eligibility, and outpatient administration.

At the same time, treatment decisions are becoming more complex. Clinicians must sequence anti-CD38 antibodies, proteasome inhibitors, immunomodulatory drugs, cereblon E3 ligase modulators, CAR-T therapies, bispecific antibodies, and supportive care while managing infections, cytopenias, cytokine release syndrome, neurotoxicity, renal impairment, bone disease, and frailty in older patients.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing multiple myeloma therapeutics across discovery, clinical development, diagnosis, pharmacovigilance, and commercial strategy. AI-enabled target identification and molecular modeling can accelerate early research for BCMA, GPRC5D, FcRH5, cereblon pathway modulators, and resistance-associated biomarkers.

In clinical development, machine learning supports trial feasibility, patient stratification, endpoint modeling, synthetic-control exploration, and real-world evidence generation. Multiple myeloma is particularly suited to AI because treatment response is measured through structured laboratory data, imaging, cytogenetics, measurable residual disease testing, and longitudinal electronic health records.

The cumulative impact is expected to be strongest where AI improves precision therapy selection, adverse-event prediction, cell-therapy manufacturing workflows, referral optimization, and earlier detection of relapse. However, industry leaders must validate algorithms in diverse populations, address data interoperability, protect patient privacy, comply with evolving AI governance expectations, and avoid model bias that could widen disparities in access to advanced therapies.

Key Regional Insights for Multiple Myeloma Therapeutics

North America remains the leading commercial region for multiple myeloma therapeutics, supported by high diagnosis rates, rapid adoption of novel agents, strong reimbursement pathways, and extensive oncology trial infrastructure. The United States is the central driver due to FDA approvals, academic cancer networks, and broad specialist use of CAR-T and bispecific therapies, while Canada contributes through guideline-driven reimbursement and organized cancer-care systems.

Europe continues to be a major region, with the European Medicines Agency and national health technology assessment bodies shaping launch timing, pricing, and reimbursement. Germany, France, Italy, Spain, and the United Kingdom show strong clinical adoption, although access can vary by budget-impact review, local treatment guidelines, and capacity for complex immunotherapy delivery.

Asia-Pacific is expanding quickly as China, Japan, South Korea, Australia, and India increase oncology spending, diagnostic capacity, local clinical development, and access to novel hematology treatments. Latin America, led by Brazil and Mexico, shows growing demand but remains constrained by reimbursement gaps and unequal specialty-care access. The Middle East is investing in tertiary oncology centers, especially in GCC countries, while Africa faces the greatest access challenges related to diagnostics, affordability, specialist availability, and consistent supply of advanced therapies.

Key Group Insights Across G7, EU, BRICS, ASEAN, GCC, and NATO

The G7 represents the most mature demand base for premium multiple myeloma therapeutics, combining advanced diagnostic pathways, high biologics utilization, established reimbursement systems, and early adoption of immunotherapies. Within this group, the United States, Japan, Germany, France, Italy, Canada, and the United Kingdom influence clinical guidelines, evidence standards, treatment sequencing, and launch prioritization.

The European Union remains a critical policy and reimbursement bloc because centralized regulatory authorization is followed by country-level pricing and health technology assessment. This structure rewards therapies that demonstrate meaningful survival benefit, deep response, quality-of-life improvement, reduced hospitalization burden, or operational advantages in outpatient care.

BRICS countries are increasingly important for patient access expansion, local manufacturing, and broader clinical trial participation, particularly China, India, and Brazil, while Russia continues to reflect a distinct reimbursement and access environment. ASEAN markets are improving cancer-care capacity but vary significantly in reimbursement readiness, diagnostic infrastructure, and specialist availability. GCC countries are adopting high-value oncology therapies through specialized centers and national health investments, while NATO membership has indirect relevance through resilient supply chains, cross-border research networks, and medicine-security planning.

Key Country Insights for Priority Multiple Myeloma Markets

The United States leads in innovation, clinical trial density, regulatory uptake, and commercialization of advanced multiple myeloma therapeutics, while Canada emphasizes evidence-based reimbursement and equitable provincial access. Mexico and Brazil are key Latin American markets where demand is rising, but patient access depends heavily on public coverage, private insurance, diagnostic availability, and concentration of specialty oncology centers.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central markets for adoption of anti-CD38 antibodies, proteasome inhibitor combinations, CAR-T therapies, and bispecific antibodies. Germany often provides early post-approval access, while France, Italy, Spain, and the United Kingdom apply rigorous value assessment, budget-impact evaluation, and managed access mechanisms. Russia remains a strategically relevant hematology market, although access to the newest therapies is shaped by reimbursement decisions, procurement systems, and local regulatory pathways.

China is scaling domestic oncology innovation and has become a major clinical development hub for cell therapies, antibodies, and combination regimens. Japan has strong uptake of precision oncology and an aging population that increases myeloma burden. India offers long-term growth potential but remains price sensitive, while Australia and South Korea demonstrate advanced specialist care, modern reimbursement systems, organized clinical networks, and increasing use of novel immunotherapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value rather than incremental regimen expansion. Durable response, measurable residual disease negativity, tolerability in older patients, outpatient feasibility, lower infection burden, renal safety, and quality-of-life outcomes are increasingly important to physicians, payers, and patients.

Manufacturers should invest in sequencing evidence across CAR-T therapies, bispecific antibodies, anti-CD38 regimens, proteasome inhibitor backbones, immunomodulatory drugs, and emerging cereblon E3 ligase modulators. Real-world evidence is essential to support reimbursement, optimize adverse-event management, and demonstrate value in patients who are older, frail, renally impaired, high-risk cytogenetic, or underrepresented in pivotal trials.

Commercial strategy should include regional access planning early in development. Scalable manufacturing, reliable cold-chain logistics, patient referral networks, digital monitoring, infection-prevention protocols, companion diagnostics readiness, and payer-aligned outcomes evidence will be decisive for expanding advanced multiple myeloma therapeutics beyond elite academic centers.

Research Methodology

This executive summary is developed using a structured secondary-research approach aligned with established market intelligence practices. Inputs include publicly available regulatory information, oncology guidelines, peer-reviewed literature, epidemiology databases, health authority publications, clinical trial registries, reimbursement documentation, and recognized cancer statistics sources such as GLOBOCAN and national cancer societies.

The methodology emphasizes triangulation across epidemiology, treatment guidelines, product approvals, reimbursement patterns, clinical trial activity, safety considerations, and regional access dynamics. Qualitative insights are evaluated against observable market signals, including label expansions, guideline incorporation, therapy sequencing trends, real-world evidence generation, and investment in oncology infrastructure.

All findings are synthesized to support executive-level decision-making across research and development, commercialization, market access, competitive intelligence, supply-chain planning, and geographic expansion in the multiple myeloma therapeutics market, while avoiding unsupported market sizing or forecasting claims.

Conclusion

The multiple myeloma therapeutics market is entering a new phase defined by immune targeting, personalized sequencing, measurable residual disease assessment, and broader use of advanced modalities. The transition from conventional combinations to CAR-T therapies, bispecific antibodies, antibody-based regimens, and next-generation small molecules is raising standards for depth and durability of response.

Growth opportunities are strongest for organizations that can combine clinical differentiation with access readiness. Evidence quality, safety management, manufacturing scalability, regional reimbursement strategy, patient identification, and real-world performance will determine long-term leadership.

As treatment options expand, the market will reward solutions that extend survival, reduce relapse risk, improve patient experience, and make innovative multiple myeloma care accessible across both developed and emerging health systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Multiple Myeloma Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Histone Deacetylase Inhibitor
7.3. Immunomodulatory Drug
7.3.1. Lenalidomide
7.3.2. Thalidomide
7.3.3. Pomalidomide
7.4. Monoclonal Antibodies
7.4.1. Daratumumab
7.4.2. Isatuximab
7.4.3. Elotuzumab
7.5. Proteasome Inhibitor
7.5.1. Bortezomib
7.5.2. Carfilzomib
7.5.3. Ixazomib
8. Multiple Myeloma Therapeutics Market, by Mode Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Multiple Myeloma Therapeutics Market, by Line of Therapy
9.1. Introduction
9.2. First-Line Therapy
9.3. Second-Line Therapy
10. Multiple Myeloma Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Online
10.3. Offline
11. Multiple Myeloma Therapeutics Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Clinics
11.4. Cancer Research Institutes
11.5. Homecare Settings
12. Multiple Myeloma Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Multiple Myeloma Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Multiple Myeloma Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. 2seventy bio, Inc.
16.2. AbbVie Inc.
16.3. Amgen Inc.
16.4. Arcellx, Inc.
16.5. AstraZeneca plc
16.6. BeiGene, Ltd.
16.7. Bluebird Bio, Inc.
16.8. Bristol-Myers Squibb Company
16.9. F. Hoffmann-La Roche Ltd.
16.10. Gilead Sciences, Inc.
16.11. GlaxoSmithKline plc
16.12. ImmunoGen, Inc.
16.13. Johnson & Johnson
16.14. Karyopharm Therapeutics Inc.
16.15. Legend Biotech Corporation
16.16. Merck & Co., Inc.
16.17. Novartis AG
16.18. Oncopeptides AB
16.19. Ono Pharmaceutical Co., Ltd.
16.20. Pfizer Inc.
16.21. Poseida Therapeutics, Inc.
16.22. Regeneron Pharmaceuticals, Inc.
16.23. Sanofi S.A.
16.24. Takeda Pharmaceutical Company Limited
16.25. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOMODULATORY DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOMODULATORY DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOMODULATORY DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL LENALIDOMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LENALIDOMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LENALIDOMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL THALIDOMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL THALIDOMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL THALIDOMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL POMALIDOMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL POMALIDOMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL POMALIDOMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DARATUMUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DARATUMUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DARATUMUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ISATUXIMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ISATUXIMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ISATUXIMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ELOTUZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ELOTUZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ELOTUZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PROTEASOME INHIBITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROTEASOME INHIBITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROTEASOME INHIBITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BORTEZOMIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BORTEZOMIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BORTEZOMIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CARFILZOMIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CARFILZOMIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CARFILZOMIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL IXAZOMIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL IXAZOMIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL IXAZOMIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 110. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 111. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 112. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 113. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 114. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 115. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 116. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 128. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 129. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 130. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 131. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 132. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 133. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 139. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 140. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 141. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 143. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 147. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 148. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 149. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 150. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 152. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 165. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 166. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 167. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 168. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 170. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 174. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 175. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 176. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 177. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 179. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 183. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 184. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 185. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 186. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 188. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 202. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 203. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 204. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 205. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 207. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 211. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 212. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 213. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 214. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 216. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 217. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 219. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 220. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 221. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 222. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 223. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 225. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 238. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 239. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 240. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 241. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 243. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 248. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 249. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 250. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 252. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 257. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 258. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 266. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 267. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 268. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 270. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 274. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 275. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 276. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 277. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 279. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 280. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 283. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 284. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 285. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 286. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 288. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 289. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 292. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 293. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 294. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 295. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 297. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 298. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 301. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 302. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 303. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 304. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 306. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 307. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 310. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 311. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 312. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 313. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2017-2032 (USD MILLION)
TABLE 322. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 323. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 324. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 327. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER,

Companies Mentioned

  • 2seventy bio, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Arcellx, Inc.
  • AstraZeneca plc
  • BeiGene, Ltd.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Legend Biotech Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Oncopeptides AB
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Poseida Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 26.38 Billion
Forecasted Market Value ( USD ) by 2032 $ 40.48 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Multiple Myeloma Drug Market - Global Forecast 2026-2032 - Product Image

Multiple Myeloma Drug Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Multiple Myeloma Drug Pipeline Analysis Report 2026 - Product Image

Multiple Myeloma Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2026-2034 - Product Image

Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2026-2034

  • Report
  • 140 Pages
  • Global
From
Multiple Myeloma Drugs Market Report 2026 - Product Image

Multiple Myeloma Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Multiple Myeloma Therapeutics - Global Strategic Business Report - Product Image

Multiple Myeloma Therapeutics - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.